Blog Category

Press Releases

Biophytis Successfully Closes its Public Offering of Share Subscription Warrants (BSA)

,

/

27 April 2020

Correction – Biophytis launches a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders

,

/

21 April 2020

Biophytis Launches COVA Clinical Study with Sarconeos (BIO101) in Covid-19

,

/

7 April 2020

Biophytis Announces Launch of a Public Offering of Share Subscription Warrants (BSA) with an Irreducible Priority Subscription Period for Existing Shareholders

,

/

7 April 2020

Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101)

,

/

7 April 2020

2019 Annual Financial Report made available

,

/

6 April 2020

Biophytis Receives Approval from the Belgian Regulatory Agency to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with DMD

,

/

30 March 2020

Biophytis Completes Recruitment of SARA-INT Phase 2b Study, Evaluating the Efficacy of Sarconeos (BIO101) in the Treatment of Sarcopenia

,

/

24 March 2020

Biophytis Reports 2019 Full Year Results and Provides Operational Update

,

/

17 March 2020

Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France

,

/

3 March 2020

Biophytis Trading will resume on February 14th, 2020 at 09:00 CET

,

/

14 February 2020

Biophytis successfully completes a € 3.3 million capital increase to strengthen its financing structure

,

/

14 February 2020